hVIVO PLC
LSE:HVO

Watchlist Manager
hVIVO PLC Logo
hVIVO PLC
LSE:HVO
Watchlist
Price: 19.5 GBX -1.02%
Market Cap: 132.7m GBX
Have any thoughts about
hVIVO PLC?
Write Note
HVO
/
Balance Sheet
/
Other Long-Term Assets

hVIVO PLC
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

hVIVO PLC
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
hVIVO PLC
LSE:HVO
Other Long-Term Assets
£4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Oxford Nanopore Technologies PLC
LSE:ONT
Other Long-Term Assets
£5.5m
CAGR 3-Years
56%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Diaceutics PLC
LSE:DXRX
Other Long-Term Assets
£1.1m
CAGR 3-Years
56%
CAGR 5-Years
78%
CAGR 10-Years
N/A
G
Genedrive PLC
LSE:GDR
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Ergomed PLC
LSE:ERGO
Other Long-Term Assets
£5.5m
CAGR 3-Years
20%
CAGR 5-Years
27%
CAGR 10-Years
N/A
C4X Discovery Holdings PLC
LSE:C4XD
Other Long-Term Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

hVIVO PLC
Glance View

Market Cap
132.7m GBX
Industry
Life Sciences Tools & Services

hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

HVO Intrinsic Value
26.37 GBX
Undervaluation 26%
Intrinsic Value
Price
What is Intrinsic Value?

See Also

What is hVIVO PLC's Other Long-Term Assets?
Other Long-Term Assets
4m GBP

Based on the financial report for Jun 30, 2024, hVIVO PLC's Other Long-Term Assets amounts to 4m GBP.

Back to Top
ALPHA SPREAD
Follow us
Join more than 211,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.